中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2008年
3期
198-202
,共5页
顾平%陈虞梅%黄钢%朱翠英%袁济民
顧平%陳虞梅%黃鋼%硃翠英%袁濟民
고평%진우매%황강%주취영%원제민
胸腔积液%癌胚抗原%CYFRA21-1%诊断,鉴别%文献工作
胸腔積液%癌胚抗原%CYFRA21-1%診斷,鑒彆%文獻工作
흉강적액%암배항원%CYFRA21-1%진단,감별%문헌공작
Pleural effusion%Carcinoembryonic antigen%CYFRA21-1%Diagnosis%differential%Documentation
目的 用Meta分析方法系统评价近10年来癌胚抗原(CEA)和细胞角蛋白19片段抗原21-1(CYFRA 21-1)在鉴别良恶性胸腔积液中的价值,并进一步比较两者在诊断效能上的差异.方法 收集1996年1月-2007年1月间国内外公开发表的关于CEA和CYFRA 21-1鉴别良恶性胸腔积液的文献,对纳入文献进行方法学质量评估后,运用Q检验评价数据的异质性,合并其灵敏度和特异性,用两者综合受试者工作特征(SROC)曲线下面积(AUC)评价和比较(Z检验)CEA和CYFRA 21-1鉴别良恶性胸腔积液的效能.结果 共有19篇文献纳入,研究对象3228例.CEA汇总的灵敏度和特异性[95%可信区间(CI)]为45.9%(43.2%~48.5%)和97.0%(96.0%~97.8%), CYFRA 21-1汇总的灵敏度和特异性(95%CI)为47.3%(44.0%~50.6%)和91.8%(89.5%~93.7%),其结果均存在明显的异质性(P<0.05).CEA和CYFRA 21-1的AUC分别为0.7691和0.8213,Z检验比较两者AUC差异无统计学意义(Z=0.45,P>0.05).结论 CEA和CYFRA 21-1在诊断良恶性胸腔积液时均具有较好的准确性.
目的 用Meta分析方法繫統評價近10年來癌胚抗原(CEA)和細胞角蛋白19片段抗原21-1(CYFRA 21-1)在鑒彆良噁性胸腔積液中的價值,併進一步比較兩者在診斷效能上的差異.方法 收集1996年1月-2007年1月間國內外公開髮錶的關于CEA和CYFRA 21-1鑒彆良噁性胸腔積液的文獻,對納入文獻進行方法學質量評估後,運用Q檢驗評價數據的異質性,閤併其靈敏度和特異性,用兩者綜閤受試者工作特徵(SROC)麯線下麵積(AUC)評價和比較(Z檢驗)CEA和CYFRA 21-1鑒彆良噁性胸腔積液的效能.結果 共有19篇文獻納入,研究對象3228例.CEA彙總的靈敏度和特異性[95%可信區間(CI)]為45.9%(43.2%~48.5%)和97.0%(96.0%~97.8%), CYFRA 21-1彙總的靈敏度和特異性(95%CI)為47.3%(44.0%~50.6%)和91.8%(89.5%~93.7%),其結果均存在明顯的異質性(P<0.05).CEA和CYFRA 21-1的AUC分彆為0.7691和0.8213,Z檢驗比較兩者AUC差異無統計學意義(Z=0.45,P>0.05).結論 CEA和CYFRA 21-1在診斷良噁性胸腔積液時均具有較好的準確性.
목적 용Meta분석방법계통평개근10년래암배항원(CEA)화세포각단백19편단항원21-1(CYFRA 21-1)재감별량악성흉강적액중적개치,병진일보비교량자재진단효능상적차이.방법 수집1996년1월-2007년1월간국내외공개발표적관우CEA화CYFRA 21-1감별량악성흉강적액적문헌,대납입문헌진행방법학질량평고후,운용Q검험평개수거적이질성,합병기령민도화특이성,용량자종합수시자공작특정(SROC)곡선하면적(AUC)평개화비교(Z검험)CEA화CYFRA 21-1감별량악성흉강적액적효능.결과 공유19편문헌납입,연구대상3228례.CEA회총적령민도화특이성[95%가신구간(CI)]위45.9%(43.2%~48.5%)화97.0%(96.0%~97.8%), CYFRA 21-1회총적령민도화특이성(95%CI)위47.3%(44.0%~50.6%)화91.8%(89.5%~93.7%),기결과균존재명현적이질성(P<0.05).CEA화CYFRA 21-1적AUC분별위0.7691화0.8213,Z검험비교량자AUC차이무통계학의의(Z=0.45,P>0.05).결론 CEA화CYFRA 21-1재진단량악성흉강적액시균구유교호적준학성.
Objective Pleural effusion is a common clinical complication caused by many benign or malignant diseases. Many published papers presented that tumor-marker assays, such as carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), played a vital role on the benign and malignant differentiation. This study aimed to reviewe currently available published papers to evaluate the clinical value of those two markers for the differentiation of benign and malignant pleural effusion. Methods All published data of pleural effusion CEA and CYFRA21-1 for the differentiation studies from year 1996 to 2007 were reviewed. By methodological qualities and Q test, 19 papers were selected into this study. The overall diagnostic sensitivity, specificity, and area under curve (AUC) from receiver operating characteristic (ROC) curve were adopted to compare the value of pleural effusion CEA and CYFRA21-1 for benign and malignant differentiation used Z test. Results There were 3228 subjects included in this Meta-analysis. The sensitivity and specificity [95% confidence interval (CI)] of CEA were 45.9%(43.2%~48.5%) and 97.0%(96.0%~97.8%), and of CYFRA21-1,47.3%(44.0%~50.6%) and 91.8%(89.5%~93.7%). AUC of CEA and CYFRA21-1 were 0.7691 and 0.8213 respectively (Z=0.45,P>0.05). Conclusion Both CEA and CYFRA21-1 are useful for the differentiation of benign and malignant pleural effusion.